Home Featured Page 41

Featured

Latest

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

Compass Provides Fuller Phase 3 Picture, MADRS Curves, on Webcast

Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or...

Ancestral Knowledge: Why Understanding the Ancient is Crucial for Western Psychedelic...

Intention, Making Space for Integration, and Finding Joy in the Mundane

The Psychedelic News Feed: March 4, 2024 – September 1, 2024

Pα+ Psychedelic Bulletin #173: Upcoming Trial Readouts to Watch; Lykos Prioritises...

Why Did the FDA Reject MDMA-Assisted Therapy for PTSD?

Could Psychedelics Transform How Doctors Treat Chronic Pain?

Finding Your Soul’s Purpose: Harnessing Psychedelic Insights for Professional Growth

How to Create Your Own Psychedelic Integration Circle

Real-World Data Reveals Variability in Access to, and Use of, Spravato

EDITOR PICKS

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine,...

After the Readout: How the Field Is Interpreting Compass’ Phase 3...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.